SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-255392
Filing Date
2021-08-25
Accepted
2021-08-24 21:42:05
Documents
14
Period of Report
2021-08-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d374477d8k.htm   iXBRL 8-K 28287
2 EX-99.1 d374477dex991.htm EX-99.1 11741
6 GRAPHIC g374477g0825062957700.jpg GRAPHIC 2897
  Complete submission text file 0001193125-21-255392.txt   173575

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctic-20210824.xsd EX-101.SCH 2903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20210824_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20210824_pre.xml EX-101.PRE 11415
7 EXTRACTED XBRL INSTANCE DOCUMENT d374477d8k_htm.xml XML 3450
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 211203497
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences